Atossa Genetics, Inc. (ATOS) Starts Presentation at LD Micro Invitational Conference

Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. The company’s leading pharmaceutical under development is Afimoxifene Topical Gel, or AfTG, which is in phase II clinical development. Atossa is also planning a phase II clinical trial using its patented intraductal Microcatheters to deliver fulvestrant to treat ductal carcinoma in-situ, or DCIS, and breast cancer. For more information, visit the company’s website at www.atossagenetics.com